KR20210040395A - 이식편 대 숙주 질환의 치료를 위한 조성물 - Google Patents

이식편 대 숙주 질환의 치료를 위한 조성물 Download PDF

Info

Publication number
KR20210040395A
KR20210040395A KR1020217005467A KR20217005467A KR20210040395A KR 20210040395 A KR20210040395 A KR 20210040395A KR 1020217005467 A KR1020217005467 A KR 1020217005467A KR 20217005467 A KR20217005467 A KR 20217005467A KR 20210040395 A KR20210040395 A KR 20210040395A
Authority
KR
South Korea
Prior art keywords
ala
leu
gly
val
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217005467A
Other languages
English (en)
Korean (ko)
Inventor
군즈버그 장 드
Original Assignee
다 볼떼라
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다 볼떼라 filed Critical 다 볼떼라
Publication of KR20210040395A publication Critical patent/KR20210040395A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217005467A 2018-08-05 2019-08-05 이식편 대 숙주 질환의 치료를 위한 조성물 Ceased KR20210040395A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18187409 2018-08-05
EP18187409.0 2018-08-05
PCT/EP2019/071026 WO2020030593A1 (en) 2018-08-05 2019-08-05 Compositions for the treatment of graft versus host disease

Publications (1)

Publication Number Publication Date
KR20210040395A true KR20210040395A (ko) 2021-04-13

Family

ID=63165229

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217005467A Ceased KR20210040395A (ko) 2018-08-05 2019-08-05 이식편 대 숙주 질환의 치료를 위한 조성물

Country Status (11)

Country Link
US (1) US20210290741A1 (https=)
EP (1) EP3829552A1 (https=)
JP (1) JP2021533150A (https=)
KR (1) KR20210040395A (https=)
CN (1) CN112689506A (https=)
AU (1) AU2019320483A1 (https=)
BR (1) BR112021002105A2 (https=)
CA (1) CA3106433A1 (https=)
IL (1) IL280589A (https=)
MX (1) MX2021001393A (https=)
WO (1) WO2020030593A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220218800A1 (en) * 2019-05-06 2022-07-14 Synthetic Biologics, Inc. Beta-lactamase compositions for treatment of graft versus host disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006249100B2 (en) 2005-05-18 2012-01-19 Assistance Publique - Hospitaux De Paris Colonic delivery of adsorbents
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
FI119190B (fi) 2006-06-21 2008-08-29 Ipsat Therapies Oy Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi
MX340822B (es) 2010-02-23 2016-07-26 Da Volterra * Formulaciones para suministro oral de adsorbentes en el intestino.
FI20105572A0 (fi) 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
EP2897594B1 (en) 2012-09-21 2020-04-08 Ferring B.V. Pharmaceutical composition
US9290754B2 (en) 2014-04-17 2016-03-22 Synthetic Biologics Inc. Beta-lactamases with improved properties for therapy
CN107148473B (zh) * 2014-10-08 2021-08-06 合成生物制品有限公司 β-内酰胺酶制剂及其用途
FR3027307B1 (fr) 2014-10-16 2016-11-04 Azurrx Sas Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant
CA3254897A1 (en) * 2014-11-25 2026-03-02 Memorial Sloan-Kettering Cancer Center Intestinal microbiota and gvhd
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome

Also Published As

Publication number Publication date
CN112689506A (zh) 2021-04-20
US20210290741A1 (en) 2021-09-23
JP2021533150A (ja) 2021-12-02
BR112021002105A2 (pt) 2021-06-01
MX2021001393A (es) 2021-04-12
IL280589A (en) 2021-03-25
CA3106433A1 (en) 2020-02-13
AU2019320483A1 (en) 2021-02-18
EP3829552A1 (en) 2021-06-09
WO2020030593A1 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
JP4908420B2 (ja) 膵機能不全を治療するための、リパーゼ、プロテアーゼおよびアミラーゼを含有する組成物
US20040147441A1 (en) Methods and reagents for preventing bacteremias
US20040127403A1 (en) Methods for treating and preventing Gram-positive bacteremias
US20210008096A1 (en) Suppression or reduction of the pathogenicity or virulence of a clostridium bacteria
JP2026035819A (ja) 移植片対宿主病の処置のためのβ－ラクタマーゼ組成物
CN110124012B (zh) 一种颗粒溶素作为多粘菌素类抗生素增效剂的应用
EP3207141B1 (fr) Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant
KR20210040395A (ko) 이식편 대 숙주 질환의 치료를 위한 조성물
US20160151333A1 (en) Methods and compositions to prevent or treat bacterial infections
KR20210040997A (ko) 항암제 효능의 개선 방법
JP3014090B2 (ja) バンコマイシン耐性菌の検出方法及び検出用培地
JP2021533150A5 (https=)
WO2022101269A1 (en) Formulations and dosage regimen for oral delivery of adsorbents in the gut
JPH11169196A (ja) バンコマイシン耐性菌の検出方法及び検出用培地

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210223

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220615

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20241113

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250122

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D